Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor by Gomes-Marcondes, M C C et al.
Development of an in-vitro model system to investigate the
mechanism of muscle protein catabolism induced by
proteolysis-inducing factor
MCC Gomes-Marcondes
1, HJ Smith
2, JC Cooper
2 and MJ Tisdale*
,2
1Department of Physiology and Biophysics, University of Campinas, UNICAMP, SP, Brazil 13083-970;
2Pharmaceutical Sciences Research Institute, Aston
University, Birmingham B4 7ET, UK
The mechanism of muscle protein catabolism induced by proteolysis-inducing factor, produced by cachexia-inducing murine
and human tumours has been studied in vitro using C2C12 myoblasts and myotubes. In both myoblasts and myotubes protein
degradation was enhanced by proteolysis-inducing factor after 24 h incubation. In myoblasts this followed a bell-shaped dose-
response curve with maximal effects at a proteolysis-inducing factor concentration between 2 and 4 nM, while in myotubes
increased protein degradation was seen at all concentrations of proteolysis-inducing factor up to 10 nM, again with a maximum
of 4 nM proteolysis-inducing factor. Protein degradation induced by proteolysis-inducing factor was completely attenuated in
the presence of cycloheximide (1 mM), suggesting a requirement for new protein synthesis. In both myoblasts and myotubes
protein degradation was accompanied by an increased expression of the a-type subunits of the 20S proteasome as well as
functional activity of the proteasome, as determined by the ‘chymotrypsin-like’ enzyme activity. There was also an increased
expression of the 19S regulatory complex as well as the ubiquitin-conjugating enzyme (E214k), and in myotubes a decrease in
myosin expression was seen with increasing concentrations of proteolysis-inducing factor. These results show that proteolysis-
inducing factor co-ordinately upregulates both ubiquitin conjugation and proteasome activity in both myoblasts and myotubes
and may play an important role in the muscle wasting seen in cancer cachexia.
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Progressive loss of lean body mass is the most debilitating and life-
threatening aspect of cancer cachexia. There may be as much as
75% loss of skeletal muscle mass while the non-muscle protein
compartment is preserved (Fearon, 1992), thus distinguishing this
syndrome from that of simple starvation. Muscle mass is determined
by both the rate of protein synthesis and the rate of protein degrada-
tion, and alteration in the balance between these two events can lead
to hypertrophy or atrophy of muscle. Thus a reduced rate of protein
synthesis and an increased rate of protein degradation was found in
newly diagnosed cancer patients with weight loss (Lundholm et al,
1976). In this study an increase in cathepsin D activity was found
in biopsies from the rectus abdominal muscle and this correlated with
the increased rate of protein degradation.
Skeletal muscle contains multiple proteolytic systems for the
breakdown of proteins including lysosomal, calcium-dependent
and ATP-ubiquitin-dependent proteolytic pathways (Lecker et al,
1999). However, skeletal muscle contains few lysosomes and
cathepsins are not involved in the breakdown of myoﬁbrillar
proteins (Lowell et al, 1986). In addition mRNA for cathepsin B
or cathepsin B and B + L activities were not found to change in
skeletal muscle of rats implanted with a cachexia-inducing tumour
(Temparis et al, 1994), although in the MAC16-induced cachexia
in mice there were increases in both cathepsins B and L (Lorite
et al, 1998). However, the contribution of this pathway and the
calcium-dependent proteolytic process to overall protein loss is
small and the ATP-ubiquitin-dependent proteolytic pathway is
generally considered to be mainly responsible for muscle protein
catabolism in cancer cachexia.
We have been investigating the role of a sulphated glycoprotein,
produced exclusively by cachexia-inducing tumours in both mouse
and man, in the catabolism of skeletal muscle in cancer cachexia
(Todorov et al, 1996a). Urinary excretion of the glycoprotein could
be detected in patients with carcinomas of the pancreas, liver,
rectum, colon, breast, lung and ovary, where the weight loss was
greater than or equal to 1 kg per month (Cariuk et al, 1997). This
material has been named proteolysis-inducing factor (PIF) because
of the ability to induce muscle protein catabolism directly, both in
isolated skeletal muscle (Lorite et al, 1997) and in murine
myoblasts in vitro (Smith et al, 1999). Administration of PIF to
non-tumour bearing mice produced a rapid decrease in body
weight (8.6% in 24 h), with speciﬁc loss of lean body mass (Lorite
et al, 1998). In PIF-treated animals there was loss of skeletal
muscle, while visceral protein in heart and kidney was conserved,
and there was even an increase in weight of the liver. Using inhi-
bitors of the proteolytic pathways, protein catabolism in skeletal
muscle was found to be mediated entirely through an ATP-depen-
dent pathway (Lorite et al, 1998).
Further studies in mice (Lorite et al, 2001) have shown PIF to
increase both mRNA and protein levels of ubiquitin, the Mr
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gastrocnemius muscle, but not in heart, suggesting activation of the
ATP-ubiquitin-dependent proteolytic pathway. A similar effect was
seen in murine myoblasts. However, it is possible that in vivo PIF
could stimulate expression of other factors, which may be respon-
sible for the effect, while myoblasts are not the best model to study
protein degradation in muscle, since they do not contain the
myoﬁbrillar proteins actin and myosin.
In order to develop an in vitro system for further mechanistic
studies a comparison has been made of the effects of PIF on both
murine myoblasts and myotubes, which contain myoﬁbrillar
proteins. This study examines the effect of both PIF concentration
and exposure time on the activity of the ubiquitin proteasome
proteolytic pathway using immunoblotting to determine the
expression of E214k, 20S and 19S proteasome subunits, while the
functional activity of the proteasome has been determined by
measuring the ‘chymotrypsin-like’ enzyme activity, the major
proteolytic activity of the proteasome, as well as myosin expression
in myotubes.
MATERIALS AND METHODS
Materials
L-[2,6-
3H] Phenylalanine (sp.act. 2.00 TBq mmol
71) was purchased
from Amersham International (Bucks, UK). Foetal calf serum (FCS),
horse serum (HS) and Dulbecco’s modiﬁed Eagle’s medium
(DMEM) were purchased from Life Technologies (Paisley, UK).
Mouse monoclonal antibody to 20S proteasome subunits a1, 2, 3,
5, 6 and 7 (clone MCP 231) was purchased from Afﬁniti Research
Products, Exeter, UK, and mouse monoclonal antibody to myosin
heavy chain was from Novocastra, Newcastle, UK. Rabbit polyclonal
antisera to ubiquitin conjugating enzyme (E214k) was a gift from Dr
Simon Wing, McGill University, Montreal, Canada and rabbit poly-
clonal antisera to the 20S proteasome b-subunit was from
Calbiochem, Nottingham, UK. Mouse anti-MSSI and anti-p42 anti-
body were a gift from Dr Jane Arnold, UK.
Cell culture
The C2C12 mouse myoblast cell line was cultured in DMEM
supplemented with 12% FCS, 1% nonessential amino acids, and
1% penicillin-streptomycin, in a humidiﬁed atmosphere of 5%
CO2 in air at 378C. Experiments were performed on cells in the
subconﬂuent state. Myotubes were formed by allowing conﬂuent
cultures to differentiate for 9 days in DMEM containing 2% HS
with changes of medium every 2 days.
Puriﬁcation of PIF
PIF was puriﬁed from solid MAC16 tumours from mice with
weight loss between 20 and 25%. The tumour homogenate was
precipitated with ammonium sulphate (40% w v
71), and the
supernatant subjected to afﬁnity chromatography using a monoclo-
nal antibody immobilized to a protein A matrix, as described
(Todorov et al, 1996a). The immunogenic fractions were concen-
trated and used for studies without further puriﬁcation, since the
major contaminant was albumin (Todorov et al, 1996b). There
was no detectable endotoxin in puriﬁed PIF preparations.
Measurement of total protein degradation
C2C12 myoblasts were seeded at 4610
4 cells per well in 2 ml
DMEM in 6-well multidishes. After 24 h cells were labelled with
L-[2,6-
3H] phenylalanine (0.67 mCi mmole
71) for a further 24 h
period, washed three-times in PBS and incubated in fresh DMEM
without phenol red (2 ml) in the presence of various concentra-
tions of PIF for a further 24 h period. The amount of
radioactivity released into the medium was determined using a
2000CA Tri-Carb liquid scintillation analyzer. Protein degradation
in myotubes was determined by the same method.
Measurement of proteasome activity
The chymotrypsin-like activity of the proteasome was determined
ﬂuorimetrically according to the method of Orino et al (1991),
with some modiﬁcations. Cells were washed twice with ice-cold
PBS and scraped from the substratum into 20 mM Tris HCl,
pH 7.5, 2 mM ATP, 5 mM MgCl2 and 1 mM dithiothreitol
(0.5 ml). The cells were dissociated by sonication with three pulses
of 15 s with 10 s intervals at 48C. The sonicate was then centri-
fuged for 10 min at 15000 r.p.m. at 48C and the resulting
supernatant (0.1 ml) was used to determine chymotrypsin-like
activity using the ﬂuorogenic substrate succinyl-LLVY-MCA
(0.1 mM) in a total volume of 0.2 ml of 100 mM Tris HCl,
pH 8.0, with or without 10 mM lactacystin for 1 h on ice. The reac-
tion was terminated by the addition of 80 mM sodium acetate,
pH 4.3 (1 ml) and the ﬂuorescence determined with an excitation
wavelength of 360 nm and an emission wavelength of 460 nm,
after further dilution with 2 ml 80 mM sodium acetate. The activity
was adjusted for the protein concentration of the sample, deter-
mined using the Bradford assay (Sigma Chemical Co., Dorset, UK).
Western blot analysis
Samples of cytosolic protein (2.5 to 5 mg) were resolved on 12%
sodium dodecylsulphate, polyacrylamide gels (SDS–PAGE) and
transferred to 0.45 mm nitrocellulose membranes (Hybond A,
Amersham, UK), which had been blocked with 5% Marvel in Tris
buffered saline, pH 7.5, at 48C overnight. The primary antibodies
were used at a 1:1500 dilution, except for the 20S proteasome b
subunit used at a 1:2000 dilution and myosin heavy chain, used
at 1:250 dilution. The secondary antibodies were peroxidase
conjugated, either goat anti-rabbit (Sigma Chemical Co., Dorset,
UK) or rabbit anti-mouse (Amersham, UK) and were used at a
1:1500 dilution. Incubation was for 1 h at room temperature
and development was by enhanced chemiluminescence (ECL)
(Amersham, UK). Blots were scanned by a densitometer to quan-
titate differences, and a parallel gel was silver stained to ensure
equal loading. The densitometry results were analysed using ‘Phor-
etix ID Advanced’ software.
Statistical analysis
Results were expressed as mean+s.e.m. Differences were deter-
mined by one-way ANOVA.
RESULTS
The effect of PIF on protein degradation in C2C12 myoblasts after
24 h incubation, as determined by the release of L-[2,6-
3H]pheny-
lalanine into the culture medium, in the presence of excess
(2 mM)phenylalanine is shown in Figure 1A. PIF enhanced protein
degradation maximally at concentrations between 2.1 and 4.2 nM,
with some indication of an enhanced degradation also at 16.7 nM
PIF. Protein degradation was not enhanced by PIF in the presence
of cycloheximide (1 mM), showing that PIF stimulation of protein
degradation required new protein synthesis.
To determine whether PIF-induced protein catabolism was
mediatedthroughtheATP-ubiquitin-dependentpathwayproteasome
functional activity was determined by measuring ‘chymotrypsin-
like’ enzyme activity, the major proteolytic activity of the b-subu-
nits. Using the ﬂuorogenic substrate succinyl LLVY-MCA an
increase in enzyme activity was detectable at concentrations of
PIF between 2 and 4 nM (Figure 1B). The effect on protein expres-
sion of proteasome subunits in the presence of PIF was determined
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1628–1633by immunoblotting. Cellular supernatants of PIF-treated cells were
Western blotted using MCP 231 antibody, a murine monoclonal to
the 20S proteasome, which reacts with the six different a-type
subunits. Three bands were detected at approximate molecular
weight of 29000, 32000 and 35000 (Figure 2A). There was an
increase in expression of all three a-subunits in the presence of
PIF, with a dose-response curve similar to that for protein degra-
dation (Figure 1A), and with maximal induction at 4.2 nM PIF.
This effect was also attenuated in the presence of cycloheximide.
The effect of 24 h incubation with PIF on the expression of the
ATPase subunit, MSSI, of the 19S proteasome regulatory complex
is shown in Figure 2B. A single band of Mr * 50000 was apparent,
which was consistent with the predicted amino acid sequence of
the ATPase MS73 (Dawson et al, 1995). As with proteasome a-
subunits maximal expression was seen at concentrations of PIF
between 2 and 4 nM (500 and 300% of the control respectively).
The effect of PIF on the expression of the Mr 14000 ubiquitin-
conjugating enzyme (E214k) is shown in Figure 2C. The antibody
recognises both isoforms of E214k, including the isoform for which
mRNA levels increase in atrophying muscle, as a single band at Mr
17000 (Rajapurohitam et al, 1999). PIF caused an increase in
expression of E214k in a concentration-dependent manner, with
maximal expression at 4.2 and 10 nM (125 and 183% of control
respectively). There was evidence for an increase in expression
for both proteasome a-subunits (Figure 3A) and E214k (Figure
3B) within only 3 h of PIF incubation, although at this time point
lower concentrations of PIF (0.4 and 1 nM) were effective. This
provides some evidence for co-ordinate upregulation of ubiquitin
conjugating enzymes and proteasome subunits.
Further studies were carried out using C2C12 myotubes, since
these contain the myoﬁbrillar proteins actin and myosin, character-
istic of skeletal muscle. The effect of PIF on total protein
catabolism, as determined by [
3H]phenylalanine release is shown
in Figure 4A. Like the myoblasts there was an increased protein
breakdown in the presence of PIF with a maximal effect at
4.2 nM at 24 h, and the effect was still apparent at 4.2 and
10 nM PIF after 48 h without further addition of PIF to the culture
system. The effect of PIF on proteasome proteolytic activity after
24 h, as determined by the ‘chymotrypsin-like’ enzyme activity is
shown in Figure 4B. A signiﬁcant increase in enzyme activity was
seen at all concentrations of PIF between 1 and 10 nM. There
was also an increased expression of the 20S proteasome a-subunits
at all concentrations of PIF between 1 and 10 nM, which increased
with increasing concentrations of PIF, with a 2.6-fold enhancement
at 10 nM PIF (P50.01 from control by densitometric analysis)
(Figure 5A). Expression of MSSI was also enhanced at all concen-
trations of PIF ranging between 4.6-fold at 1 nM (P50.01 from
control) to 7.2-fold at 10 nM PIF (P50.05 from control) (Figure
5B). PIF-treatment also induced an increase in expression of p42,
an ATPase subunit of the 19S regulator that promotes ATP-depen-
dent association of the 20S proteasome with the 19S regulator to
form the 26S proteasome (Tanahashi et al, 1999), but there was less
of a clear-cut dose–response relationship. A similar increase in
expression was seen with E214k (Figure 5C). All concentrations of
PIF above 1 nM produced a signiﬁcant (P50.01 from control)
increase in E214k, which with a 2.8-fold enhancement at 10 nM
was similar to that observed with the 20S a-subunit expression
(Figure 5A). Myosin expression was reduced as the concentration
of PIF increased (Figure 5D, E) in inverse proportion to activation
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Figure 1 (A) Effect of PIF on total protein degradation in C2C12 myo-
blasts, either in the presence of excess phenylalanine (2 mM) (solid circle)
or cycloheximide (1 mM) (open circle). Measurements were made 24 h
after the addition of PIF and are shown as mean+s.e.m where n=6. Differ-
ences from controls in the absence of PIF are indicated as a, P50.05 or b,
P50.01. (B) Chymotryptic activity of soluble extracts of C2C12 myoblasts
determined using the ﬂuorogenic substrate sucLLVY-MCA after treatment
with PIF for 24 h. Results are shown as mean+s.e.m where n=9.
A     B    C     D     E      F           G     H       I     J     K      L
— 33.4 kDa
66 kDa —
46 kDa — 
A             B            C               D             E                F
21.5 kDa —
14.3 kDa — 
A              B            C                D              E                F
A
B
C
Figure 2 (A) Western blot of soluble extracts of C2C12 myoblasts de-
tected with MCP231, a murine monoclonal antibody to the proteasome a-
subunits after treatment of cells with PBS (A) or 1 (B), 2 (C), 4 (D), 10.5 (E)
or 17 nM PIF (F) alone or with cycloheximide (1 mM) (G) or with cyclohex-
imide (1 mM) plus 1 (H), 2 (I), 4 (J), 10.5 (K) or 17 nM PIF (L). (B) Western
blot analysis of soluble extracts of C2C12 myoblasts either untreated (A) or
treated with 0.4 (B), 1 (C), 2 (D), 4 (E) or 10 nM PIF (F) and detected with
mouse anti-human MSSI antibody. (C) Western blot analysis of soluble ex-
tracts of C2C12 myoblasts either untreated (A) or treated with 0.4 (B), 1
(C), 2 (D), 4 (E) or 10 nM PIF (F) and detected with E214k rabbit polyclonal
antisera.
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British Journal of Cancer (2002) 86(10), 1628–1633 ã 2002 Cancer Research UKof expression of the 20S proteasome (Figure 5A). There was still an
increased expression of the proteasome, as detected by the b-subu-
nit, 48 h after the original addition of PIF at concentrations of PIF
between 10 nM (three-fold) and 1 nM (two-fold) (Figure 6A).
There was also an increased expression of E214k (1.5-fold) at these
concentrations, but also an increased expression (two-fold) at
20 nM PIF (Figure 6B). Since protein degradation was not
increased at 20 nM PIF (Figure 4A) this suggests that proteasome
subunit induction rather than ubiquitin-conjugating enzymes are
rate-limiting in protein catabolism.
DISCUSSION
The ubiquitin-proteasome system is the major pathway for selective
protein degradation in eukaryotic cells, and is involved not only in
protein catabolism in skeletal muscle, but numerous other
processes, such as progression of the cell cycle, transcription, devel-
opment, growth, and atrophy of developed tissues (Kornitzer and
Ciechanover, 2000). In this process proteins are marked for degra-
dation by attachment of a polyubiquitin chain, via the ubiquitin
activating enzyme (E1), which conjugates ubiquitin through a
thioester bond in an ATP-requiring reaction; a trans-esteriﬁcation
reaction, whereby the activated ubiquitin is transferred to a
cysteine residue in the active site of the ubiquitin-conjugating
enzyme (E2), suggested to be a rate-limiting step in the pathway
(Wing and Banville, 1994), and a ubiquitin-protein ligase (E3),
which is responsible for substrate recognition and polyubiquitina-
tion. Polyubiquitinated proteins are degraded into small peptides
by a large multicatalytic protease, the 26S proteasome. This path-
way plays an important role in muscle protein degradation
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Figure 3 Western blot of soluble extracts of C2C12 myoblasts treated
with PIF for 3 h and detected with MCP231 antibody (A)o rE 2 14k rabbit
polyclonal antisera (B).
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Figure 4 (A) Effect of PIF on total protein degradation in C2C12 myo-
tubes after 24 h (6) and 48 h (solid square) incubation. Measurements
were made in the presence of excess (2 mM) phenylalanine and are the
average of nine determinations. Differences from controls in the absence
of PIF are indicated as a, P50.05 and b, P50.01. (B) Chymotryptic activity
of soluble extracts of C2C12 myotubes after treatment with PIF for 24 h.
Values shown represent mean+s.e.m where n=8. Differences from con-
trols in the absence of PIF are shown as a, P50.05 and b, P50.01.
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Figure 5 Western blot of soluble extracts of C2C12 myotubes either un-
treated or treated with PIF at a concentration of 1, 2, 5, 8 or 10 nM for 24 h
and detected with either (A) MCP231 antibody directed to the protea-
some a-subunits, (B) Mouse anti-human MSSI antibody, (C)E 2 14k rabbit
polyclonal antiserum, or (D) Mouse monoclonal antibody directed to myo-
sin heavy chain. (E) Shows a densitometric analysis of myosin heavy chains
from four separate blots, n=8. Differences from control are shown as a,
P50.05 and b, P50.01.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1628–1633induced, not only in cancer cachexia (Temparis et al, 1994; Lorite
et al, 1998), but also in starvation (Wing and Goldberg, 1993),
sepsis (Tiao et al, 1994), metabolic acidosis (Mitch et al, 1994)
and denervation atrophy (Medina et al, 1995).
Previous studies (Smith et al, 1999) have established the C2C12
murine myoblast cell line to be an appropriate surrogate model
for studying protein degradation induced by PIF, possibly through
the mediation of 15-HETE. In this study we have shown PIF to co-
ordinately upregulate the proteasome chymotrypsin-like activity in
this cell line, as well as expression of the 20S proteasome a-type
subunits, MSSI, an ATPase subunit of the 19S complex and the
Mr 14000 E2 ubiquitin-conjugating enzyme, as determined by
Western blotting. We have chosen to measure the chymotrypsin-
like activity of the proteasome in view of recent observations that
this is rate limiting in proteasome-dependent protein degradation
(Kisselev et al, 1999). Although most studies have measured mRNA
as a measure of gene expression we have measured intracellular
protein levels and functional activity of the proteasome, because
of reports (Kanayama et al, 1991; Shimbara et al, 1992) that in
various cells elevated concentrations of mRNA of proteasome
subunits were not found to be accompanied by increased concen-
trations or activities of proteasomes. In addition we have chosen to
measure E214k and 20S/19S proteasome expression as a measure of
the ubiquitin-proteasome pathway, rather than changes in ubiqui-
tin expression and conjugation, because an increase in ubiquitin
may signal an increased cell death through apoptosis (Soldatenkov
and Dritschilo, 1997), rather than an increase in proteolysis. Thus,
although the enhanced protein degradation in rat skeletal muscle in
vivo after TNF-a administration is associated with an increase in
gene transcription, and higher levels of free and conjugated ubiqui-
tin (Garcia-Martinez et al, 1993), there is no evidence for an
increase in proteasome expression in vitro (Ebisui et al, 1995),
although an increased ubiquitin gene expression was still observed
(Llovera et al, 1997). In the muscles of mice bearing the colon 26
tumour loss of muscle mass was associated with an increase in
expression of both polyubiquitin and proteasome subunits. Treat-
ment with an anti-IL-6 receptor antibody reduced polyubiquitin
expression, but had no effect on expression of proteasome subunits
(Tsujinaka et al, 1996).
As in a previous study (Smith et al, 1999) PIF-induced protein
degradation in C2C12 myoblasts followed a bell-shaped dose-
response curve with maximal effects at a PIF concentration
between 2 and 4 nM. In contrast there was no evidence of down-
regulation of protein degradation in myotubes with an increased
level found above a threshold concentration of 1 nM PIF. However,
the concentration of PIF required to induce protein catabolism was
similar in both myoblasts and myotubes. Protein degradation
induced by PIF in myoblasts was completely attenuated in the
presence of cycloheximide, suggesting the requirement for new
protein synthesis to affect protein catabolism. In both myoblasts
and myotubes PIF induced co-ordinate upregulation of both 20S
proteasome a-subunits and the 19S regulator, as well as E214k.
Proteasome functional activity, as determined by the ‘chymotryp-
sin-like’ enzyme activity, was also increased in both cell lines at
concentrations of PIF enhancing expression of the proteasome a-
subunits, while in myotubes the expression of myosin was
decreased.
This study shows co-ordinate upregulation of both the 20S
proteasome a-subunits and the 19S regulator, MSSI, an ATPase,
which is thought to provide energy, both for the association of
the 20S proteasome with the 19S complex, and to inject the
substrate into the proteolytic chamber of the 20S proteasome.
MSSI was found to be increased in the wasting muscle of rats
bearing the Yoshida sarcoma (Attaix et al, 1997), and has been
suggested to facilitate the rapid proteolysis of muscle proteins
in cancer cachexia. Expression of MSSI has been suggested to
be regulated independently of the 20S proteasome subunits, since
the increased expression of MSSI was normalised in cachectic rats
given pentoxifylline, but not tobafylline, although both suppressed
the enhanced proteolysis (Attaix et al, 1997). However, in the
present study the expression of both MSSI and the 20S protea-
some a-subunits appeared to be regulated co-ordinately,
suggesting central control of the whole cascade by PIF. The effect
of PIF was evident within as little as 3 h and persisted for a 48 h
period. However, at 48 h E214k expression was elevated at
concentrations of PIF that had no effect on protein degradation.
This suggests that ubiquitin-conjugation is not rate-limiting for
proteolysis and that this requires an induced expression of
proteasome subunits. This conclusion is similar to that reached
by Temparis et al (1994), from a study in rats bearing the Yoshi-
da sarcoma, where a signiﬁcant reduction in protein mass was
observed in the extensor digitorum longus (EDL) muscle close
to the tumour, but not in the tibalis anterior (TA) muscle. An
increased mRNA expression for ubiquitin, E214k and the protea-
some subunits C8 and C9 was found in the EDL muscle, but
not in the TA muscle, where only mRNA for ubiquitin and
E214k was increased. This suggested that increased mRNA expres-
sion for ubiquitin and E214k came ﬁrst, but that increased gene
expression of proteasome subunits was essential for enhanced
protein catabolism. This conclusion is also supported from
studies of skeletal muscle during cancer cachexia where an eleva-
tion of the high molecular mass conjugates of ubiquitin is
observed (Lorite et al, 1998), suggesting that this step is not rate
limiting in proteolysis. Thus proteasome catalytic activity rather
than substrate ubiquitination appear to be the rate-limiting step
in protein catabolism.
Further studies will concentrate on the mechanism by which PIF
leads to upregulation of the ubiquitin-proteasome pathway and
inhibitors of this process.
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Figure 6 Western blot of soluble extracts of C2C12 myotubes either un-
treated or treated with PIF at a concentration of 1, 2, 4, 10 or 20 nM for
48 h and detected with either 20S proteasome b-subunit rabbit polyclonal
antisera (A)o rE 2 14k rabbit polyclonal antisera (B).
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